A Review of Advances in the Surgical Treatment of Coronary Heart Disease and Lung Cancer

被引:3
|
作者
Hong, Yang [1 ]
Wei, Shixiong [1 ]
Tang, Mingbo [1 ]
Liu, Wei [1 ]
机构
[1] First Hosp Jilin Univ, Dept Thorac Surg, Changchun 130021, Jilin, Peoples R China
来源
HEART SURGERY FORUM | 2023年 / 26卷 / 05期
关键词
coronary heart disease; lung cancer; surgical treatment; ARTERY-BYPASS SURGERY; LONG-TERM SURVIVAL; LENGTH-OF-STAY; CARDIOPULMONARY BYPASS; HIGH-RISK; ON-PUMP; PULMONARY RESECTION; NONCARDIAC SURGERY; MYOCARDIAL REVASCULARIZATION; THORACOSCOPIC LOBECTOMY;
D O I
10.59958/hsf.5877
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Lung cancer is currently the most prevalent and fatal malignant tumor in China. Additionally, the incidence of coronary heart disease is steadily increasing. Both diseases exhibit a higher risk of mortality with age, particularly among elderly patients. Moreover, these diseases are interconnected and share common risk factors. However, the treatment options for patients suffering from both lung cancer and coronary heart disease lack clarity and standardized criteria. This article critically examines the literature on surgical interventions for patients with lung cancer complicated 2021 to December 2022. It summarizes the safety and effectiveness of these interventions and highlights the various surgical options available for different patient profiles.
引用
收藏
页码:E656 / E665
页数:10
相关论文
共 50 条